Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Andreea D. Stuparu; Joseph R. Capri; Catherine A.L. Meyer; Thuc M. Le; Susan L. Evans-Axelsson; Kyle Current; Mark Lennox; Christine E. Mona; Wolfgang P. Fendler; Jeremie Calais; Matthias Eiber; Magnus Dahlbom; Johannes Czernin; Caius G. Radu; Katharina Lückerath; Roger Slavik

doi:10.2967/jnumed.120.256263

Research ArticleTheranostics

Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Andreea D. Stuparu, Joseph R. Capri, Catherine A.L. Meyer, Thuc M. Le, Susan L. Evans-Axelsson, Kyle Current, Mark Lennox, Christine E. Mona, Wolfgang P. Fendler, Jeremie Calais, Matthias Eiber, Magnus Dahlbom, Johannes Czernin, Caius G. Radu, Katharina Lückerath and Roger Slavik

Journal of Nuclear Medicine July 2021, 62 (7) 989-995; DOI: https://doi.org/10.2967/jnumed.120.256263

Andreea D. Stuparu

1Atreca Inc., South San Francisco, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Joseph R. Capri

2AstraZeneca, Chemical Biology Group, Waltham, Massachusetts;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Catherine A.L. Meyer

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thuc M. Le

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Susan L. Evans-Axelsson

4Department of Translational Medicine, Division of Urological Cancers, Skåne University Hospital Malmö, Lund University, Lund, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kyle Current

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark Lennox

5School of Electronics, Electrical Engineering, and Computer Science, Queen’s University Belfast, Belfast, United Kingdom:

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christine E. Mona

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

8Department of Urology, Institute of Urologic Oncology, UCLA, Los Angeles, California; and

9Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

6Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeremie Calais

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

8Department of Urology, Institute of Urologic Oncology, UCLA, Los Angeles, California; and

9Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

7Clinic for Nuclear Medicine, Technical University Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Magnus Dahlbom

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johannes Czernin

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

8Department of Urology, Institute of Urologic Oncology, UCLA, Los Angeles, California; and

9Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Caius G. Radu

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

9Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katharina Lückerath

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

8Department of Urology, Institute of Urologic Oncology, UCLA, Los Angeles, California; and

9Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Roger Slavik

3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 7

July 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Journal of Nuclear Medicine Jul 2021, 62 (7) 989-995; DOI: 10.2967/jnumed.120.256263

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Journal of Nuclear Medicine Jul 2021, 62 (7) 989-995; DOI: 10.2967/jnumed.120.256263

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
Signaling Network Response to {alpha}-Particle-Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

Google Scholar

Theranostics

Determination of the Intralesional Distribution of Theranostic ¹²⁴I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
¹⁷⁷Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer

Show more Theranostics

Basic

Dopamine D₁ Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
Synthesis and Preclinical Evaluation of a ⁶⁸Ga-Labeled Adnectin, ⁶⁸Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Show more Basic

Keywords

[225Ac]Ac-PSMA
[177Lu]Lu-PSMA
prostate cancer
proteomics/phosphoproteomics
DNA damage response

Main menu

User menu

Search

Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Theranostics

Basic

Similar Articles

Keywords